Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Особенности ведения пациентов с себорейным дерматитом

https://doi.org/10.33667/2078-5631-2021-9-29-32

Полный текст:

Аннотация

Modern therapeutic views on the pathogenesis of acne indicate the role of permanent inflammation and expand the arsenal of medicines and combined techniques necessary for the successful treatment of this chronic skin disease. The complex process of immune inflammation in acne with the participation of pro-inflammatory cytokines is due to the interaction of trigger factors and factors of innate immunity. It was found that C. acne is able to interact with markers of increased immunity, such as Toll-like and protease-activated receptors. Based on a detailed analysis of the literature in search systems like PubMed, eLibrary.ru, CyberLeninka, it was found that one of the key roles in inflammation in acne belongs to matrix metalloproteinases. Thus, C. acnes are involved in many processes in the pathogenesis of acne, including inflammation, hyperkeratosis and hyperproduction of sebum, which necessitates its eradication and is an important component of complex therapy. Minocycline (Minolexin) is a highly effective drug for the treatment of moderate to severe forms of acne, including a low-dose regimen, and is included in the European Treatment Guidelines. Minocycline is considered the most powerful inhibitor of MMP, has a pronounced anti-inflammatory effect and a high level of lipophilicity, quickly penetrates the lipid layer of the bacterium and intensively accumulates in the sebaceous glands.

Об авторе

Е. М. Маркелова
ГБУЗ «Городская поликлиника № 2 Департамента здравоохранения Москвы»
Россия

Маркелова Екатерина Максимовна, врач-дерматовенеролог, косметолог



Список литературы

1. Bickers D. R., Lim H. W., Margolis D., Weinstock M. A., Goodman C., Faulkner E. et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J. Am. Acad. Dermatol. 2006. Vol. 55. P. 490–500.

2. Jonas A. Adalsteinsson, Shivani Kaushik, Sonal Muzumdar, Emma Guttman-Yassky, Jonathan Ungar. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Experimental Dermatology Volume 29, Issue 5. 03 March 2020.p. 481–489.

3. Borda LJ, Perper M, Keri JE. Treatment of seborrheic dermatitis: a comprehensive review. J Dermatolog Treat. 2019; 30 (2): 158–169. https://doi.org/10.1080/09546634.2018.1473554

4. Полонская А. С., Шатохина Е. А., Круглова Л. С. Себорейный дерматит: современные представления об этиологии, патогенезе и подходах к лечению. Клиническая дерматология и венерология. 2020; 19 (4): 451–458. https://doi.org/10.17116/klinderma202019041451

5. Dan Tucker, Sadia Masood. Seborrheic Dermatitis In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2020 Jan. 2020 Oct 3.

6. Okokon EO, Verbeek JH, Ruotsalainen JH, Ojo OA, Bakhoya VN (2015) Topical antifungals for seborrheic dermatitis. Cochrane Database Syst Rev (4): 1–229

7. Л. С. Круглова, Д. В. Федоров, А. Г. Стенько, Н. В. Грязева, А. Б. Яковлев. Актуальные рекомендации по применению многокомпонентного препарата в дерматологии. Медицинский алфавит. 2019. Т. 2. № 26 (401). С. 67–72. https://doi.org/10.33667/2078–5631–2019–2–26(401)-67–72

8. Schmidt-Rose T, Braren S, Folster H, Hillemann T, Oltrogge B, et al. (2011) Efficacy of a piroctone olamine/climbazol shampoo in comparison with a zinc pyrithione shampoo in subjects with moderate to severe dandruff. Int J Cosmet Sci 33(3): 276–282.

9. Goldust M, Rezaee E, Raghifar R, Hemayat S (2013) Treatment of seborrheic dermatitis: the efficiency of sertaconazole 2 % cream vs tacrolimus 0.03 % cream. Ann Parasitol 59 (2): 73–77.

10. Lebwohl M, Plott T (2004) Safety and efficacy of ciclopirox 1 % shampoo for the treatment of seborrheic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int J Dermatol 43(Suppl1): 17–20.

11. Sugita T, Tajima M, Tsubuku H, Tsuboi R, Nishikawa A. A new calcineurin inhibitor, pimecrolimus, inhibits the growth of Malassezia spp. Antimicrob Agents Chemother. 2006; 50 (8): 2897–2898. https://doi.org/10.1128/AAC.00687–06

12. Borda LJ, Wikramanayake TC. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J Clin Investig Dermatol. 2015; 3 (2): 10. https://doi.org/10.13188/2373–1044.1000019

13. Болотная Л. А. Возможности такролимуса в лечении больных хроническими дерматозами. Украинский журнал дерматологии, венерологии, косметологии. 2012; 2 (42): 27–32.

14. Sébastien Menzinger, Emmanuel Laffitte. Dermitesé borrhéique: manifestations cliniques et priseen charge. Rev Med Suisse 2011; volume 7. 752–758.

15. Ghodsi SZ, Abbas Z, Abedeni R. Efficacy of Oral Itraconazole in the Treatment and Relapse Prevention of Moderate to Severe Seborrheic Dermatitis: A Randomized, Placebo-Controlled Trial. Am J Clin Dermatol. 2015; 16 (5): 431–437. https://doi.org/10.1007/s40257–015–0133–9

16. Cömert A, Bekiroglu N, Gürbüz O, Ergun T. Efficacy of oral fluconazole in the treatment of seborrheic dermatitis: a placebo-controlled study. Am J Clin Dermatol. 2007; 8 (4): 235–238. https://doi.org/10.2165/00128071–200708040–00005

17. Gupta AK, Richardson M, Paquet M. Systematic review of oral treatments for seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2014; 28 (1): 16–26. https://doi.org/10.1111/jdv.12197

18. King K, Jones DH, Daltrey DC, Cunliffe WJ.A double-blind study of the effects of 13-cisretinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol. 1982; 107 (5): 583–90.

19. De Souza Leão Kamamoto C, Sanudo A, Hassun KM, Bagatin E. Low-dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. Int J Dermatol. 2017; 56 (1): 80–85. https://doi.org/10.1111/ijd.13408

20. Dahl KB, Reymann F. Photochemotherapy in erythrodermicseborrhoic dermatitis. Arch Dermatol. 1977; 113 (9): 1295–6.

21. Давидович М. И. Опыт применения УФБ 311 нм в лечении себорейного дерматита. Регулярные выпуски «РМЖ», № 9 от 20.05.2015.

22. Pirkhammer D, Seeber A, Honigsmann H, Tanew A. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrheic dermatitis. Br J Dermatol. 2000; 143 (5): 964–8.

23. Sigmundsdottir H., Johnston A., Gudjonsson J. E. et al. Narrowband-UVB irradiation decreases the production of pro-inflammatory cytokines by stimulated T cells. Arch. Dermatol. Res. 2005. Vol. 297, № 1. P. 39–42.

24. Gambichler T, Breuckmann F, Boms S, Altmeyer P, Kreuter A. Narrowband UVB phototherapy in skin conditions beyond psoriasis. J Am Acad Dermatol. 2005; 52 (4): 660–670. https://doi.org/10.1016/j.jaad.2004.08.047

25. Илешина Т. В. Себорейный дерматит. Русский медицинский журнал. 2004; 12 (5): 324–26.

26. Gaitanis G, Magiatis P, Hantschke M, Bassukas ID, Velegraki A. The Malassezia genus in skin and systemic diseases. Clin Microbiol Rev. 2012; 25 (1): 106–141.


Для цитирования:


Маркелова Е.М. Особенности ведения пациентов с себорейным дерматитом. Медицинский алфавит. 2021;(9):29-32. https://doi.org/10.33667/2078-5631-2021-9-29-32

For citation:


Markelova E.M. Features of management of patients with seborrheic dermatitis. Medical alphabet. 2021;(9):29-32. (In Russ.) https://doi.org/10.33667/2078-5631-2021-9-29-32

Просмотров: 21


ISSN 2078-5631 (Print)